Completed

Randomized, Double-blind Trial Evaluating the Impact of the Consumption of GOS (Galacto Oligosacharides) on the Adult Microbiome

What is being tested

Milk powder

Dietary Supplement

Who is being recruted

From 18 to 55 Years

+20 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Prevention Study

Placebo-Controlled

Interventional

Study Start: October 2021

See protocol details

Summary

Principal SponsorSociété des Produits Nestlé (SPN)

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: October 27, 2021

Actual date on which the first participant was enrolled.

The aim of this study is to evaluate the bifidogenic effect and other potentially beneficial effects on the microbiome of GOS.

Official TitleRandomized, Double-blind Trial Evaluating the Impact of the Consumption of GOS (Galacto Oligosacharides) on the Adult Microbiome

NCT05207839

Principal SponsorSociété des Produits Nestlé (SPN)

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

26 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

4 inclusion criteria required to participate

Age 18-55 years,

Healthy participants, both male and female

BMI in the normal and overweight range 18.5 ≤ BMI ≤ 29.9 kg/m2

Able to understand and to sign a written informed consent prior to study enrolment

16 exclusion criteria prevent from participating

Known chronic diseases or conditions for which the investigators/investigation team deem as not suitable for study participation,

Known food allergy and intolerance e.g. lactose intolerance,

Habitually, have < 5 spontaneous bowel movements on average per week,

Chronic or recurrent diarrhoea with spontaneous bowel movements > 2 per day

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator

Group II

Placebo

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Clinical Innovation Lab

Lausanne, SwitzerlandOpen Clinical Innovation Lab in Google Maps

CompletedOne Study Center